Curis, Inc. Reaches First Preclinical Milestone In Hair Growth Program With Procter & Gamble
CAMBRIDGE, Mass.--(BUSINESS WIRE)--March 21, 2006--Curis, Inc. (NASDAQ: CRIS), a therapeutic drug development company, today announced that it has reached the first preclinical milestone in a hair growth program with Procter & Gamble Pharmaceuticals, a division of The Procter & Gamble Company (NYSE: PG). The program is focused upon the potential development of a topical Hedgehog agonist for hair growth disorders, such as male pattern baldness and female pattern hair loss. As part of the initial agreement signed in September of 2005, P&G agreed to pay Curis up to $2.8 million in preclinical milestones. The first of two preclinical milestones has now been successfully completed.